BPC-157 (Body Protection Compound-157)
BPC-157 is a synthetic peptide derived from a protein found in human gastric juice. It has become one of the most widely researched and discussed peptides in the health and fitness community, with potential applications in tissue repair, gut health, and recovery. Here's everything you need to know — kept current as the regulatory landscape evolves.
⚖️ Legal & Regulatory Status
Last updated: April 15, 2026
BPC-157 is currently on the FDA's Category 2 bulk drug substances list, which means licensed compounding pharmacies cannot legally compound it for human use under 503A regulations.
However, this is changing. On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that BPC-157 is among 14 peptides being moved back to Category 1 status. As of April 2026, the formal FDA rule change has not yet been published, but the direction is clear. Once published — expected Q2–Q3 2026 — licensed compounding pharmacies will again be able to prepare BPC-157 under a physician's prescription.
Current status summary:
- ❌ Cannot be legally compounded by pharmacies right now
- ✅ Reclassification to Category 1 announced February 27, 2026
- ⏳ Formal FDA publication pending — expected Q2/Q3 2026
- ⚠️ "Research use only" gray market sales continue but carry legal risk for sellers
- ✅ Not a controlled substance — possession is not illegal for individuals
BPC-157 is not FDA-approved as a drug. Even after reclassification, it will remain an off-label therapeutic requiring physician supervision.
🔬 What the Research Says
Last updated: April 15, 2026
BPC-157 has been studied primarily in animal models (rats and mice), where it has shown a wide range of regenerative and protective effects. Human clinical trials are limited but growing.
What preclinical research shows:
- Tissue and tendon repair: Multiple studies show accelerated healing of tendons, ligaments, and muscles. BPC-157 appears to upregulate growth hormone receptors in tendon fibroblasts.
- Gut health: Strong evidence in animal models for healing of gastric ulcers, IBD-like conditions, and intestinal damage from NSAIDs. This is the most replicated finding in the literature.
- Neuroprotective effects: Animal studies suggest potential in reducing damage from traumatic brain injury and improving recovery from nerve damage.
- Anti-inflammatory: Appears to modulate nitric oxide systems and reduce systemic inflammation.
- Bone healing: Studies show improved healing of bone fractures and osteoporosis-related damage.
Important caveats: The vast majority of BPC-157 research is preclinical (animal studies). Human pharmacokinetics, dosing, and long-term safety profiles are not well established. Extrapolating animal data directly to humans should be done with caution. No large Phase 3 human trials have been completed as of 2026.
Key published studies (open access): Sikiric et al. (multiple papers via PubMed Central) represent the core of the research base. Most are available free at pmc.ncbi.nlm.nih.gov.
💬 Community Interest
Last updated: April 15, 2026
BPC-157 is consistently one of the most discussed peptides across fitness, biohacking, and longevity communities. On r/Peptides, it is routinely in the top 5 most discussed compounds.
The most common use cases people discuss: tendon and joint injuries (especially chronic issues unresponsive to other treatments), gut problems including gastritis and IBD, post-surgery recovery, and as part of injury prevention protocols for athletes. Many users report significant benefits for injuries that "nothing else helped," though this is anecdotal.
The biggest community concern right now is sourcing — with the gray market tightening and compounding access not yet restored, people are asking where to get it legally. The reclassification announcement has generated significant excitement and anticipation.
📅 Timeline of Changes
Last updated: April 15, 2026
- 2023: FDA places BPC-157 on Category 2 list, restricting compounding pharmacy access
- 2024: Enforcement tightens; multiple gray-market vendors receive warning letters
- June 2025: FDA raids Amino Asylum warehouse — first physical enforcement action against a peptide vendor
- Feb 27, 2026: RFK Jr. announces BPC-157 among 14 peptides returning to Category 1
- March 2026: Formal FDA publication still pending
- Q2–Q3 2026: Expected date for formal reclassification rule publication
📄 Download Research Brief
Want a comprehensive, printable summary of BPC-157 research, dosing protocols discussed in the literature, and current legal status to share with your doctor?
Deep-dive research brief available
10 pages covering mechanism of action, research findings, dosing protocols, and safety profile.
BPC-157 Research Brief $9Updated whenever significant new research or regulatory changes occur. Purchase once, re-download free forever.
PeptideWatch monitors FDA announcements, PubMed, and regulatory filings daily. This page updates automatically when new information is available. Subscribe to our newsletter to get notified.